Log In
Print
BCIQ
Print
Print this Print this
 

Biomarker risk assignment algorithm

  Manage Alerts
Collapse Summary General Information
Company Zinfandel Pharmaceuticals Inc.
DescriptionGenetics-based biomarker risk assignment algorithm based on APOE and TOMM40 genotypes and age
Molecular Target Apolipoprotein E (APOE) ; Translocase of outer mitochondrial membrane 40 homolog (TOMM40) (TOM40)
Mechanism of Action 
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentPhase III
Standard IndicationNeurology, Diagnostic
Indication DetailsPredict onset of mild cognitive impairment (MCI) due to Alzheimer's disease (AD)
Regulatory Designation

Partner

Takeda Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today